Who are Insulin therapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): insulin-like growth factor I, continuation of oxytocin administration, ACTH, Parathyroid Hormone (PTH), somatostatin infusion, Intravenous Oxytocin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/insulin-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Insulin therapy — Competitive Intelligence Brief

Insulin therapy (Insulin therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Peptide hormone. Area: Endocrinology / Diabetes.

phase 3 Peptide hormone Insulin receptor (INSR) Endocrinology / Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Insulin therapy (Insulin therapy) — Shanghai Jiao Tong University School of Medicine. Insulin therapy replaces or supplements the body's own insulin to regulate blood glucose by promoting glucose uptake into cells and storage as glycogen.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Insulin therapy TARGET	Insulin therapy	Shanghai Jiao Tong University School of Medicine	phase 3	Peptide hormone	Insulin receptor (INSR)
insulin-like growth factor I	insulin-like growth factor I	Children's Hospital of Philadelphia	marketed	Growth factor; recombinant peptide hormone	IGF-1 receptor (IGF1R)
continuation of oxytocin administration	continuation of oxytocin administration	Assistance Publique - Hôpitaux de Paris	marketed	Peptide hormone / Oxytocin receptor agonist	Oxytocin receptor (OXTR)
ACTH	ACTH	Providence Health & Services	marketed	Corticotropin; peptide hormone	Melanocortin-2 receptor (MC2R)
Parathyroid Hormone (PTH)	Parathyroid Hormone (PTH)	Takeda	marketed	Peptide hormone / PTH1 receptor agonist	PTH1 receptor (PTHR1)
somatostatin infusion	somatostatin infusion	Hospices Civils de Lyon	phase 3	Peptide hormone	Somatostatin receptors (SSTR1, SSTR2, SSTR3, SSTR4, SSTR5)
Intravenous Oxytocin	Intravenous Oxytocin	University of Wisconsin, Madison	phase 3	Peptide hormone	Oxytocin receptor (OXTR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Peptide hormone class)

Hospices Civils de Lyon · 1 drug in this class
Shanghai Jiao Tong University School of Medicine · 1 drug in this class
University of Ottawa · 1 drug in this class
University of Wisconsin, Madison · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Insulin therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/insulin-therapy. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab